投资快报 3

葉芬

如果USD 1.50，我也扫货。
bennywt 发表于 22-9-2010 02:48 PM

怕是一開市就 3.50 呵呵







開玩笑的啦

葉芬

葉芬，可以介绍高股息的美国股吗？。。谢谢
carrien_foong 发表于 21-9-2010 11:42 PM

在PM回你了。
請查看。



P/s: 請問你是姓 馮 嗎？

roberto

回复 1101# 葉芬

3.50 ?? 太高了啦 ! 我暂时要2.80就够了

葉芬

回复  葉芬

3.50 ?? 太高了啦 ! 我暂时要2.80就够了
roberto 发表于 22-9-2010 03:42 PM

小弟，別假假的啦， 3.50 太高？那天還聽你講要.............













US$5 !

葉芬

好啦。今天早放工，回家囉。。。

祝大家 “中秋節快樂”

CHLaw

大家猜猜 Friday 開市會是多少$$$?

roberto

开市1.80
闭市2.00

葉芬

开市1.80
闭市2.00
roberto 发表于 22-9-2010 05:24 PM

呵呵 你很敢開價哦。




我說 意思意思 1.60 就好。

CHLaw

http://caps.fool.com/Blogs/ssn-update-trading-halt/449940

SSN Update - Trading Halt

September 22, 2010 – Comments (1) | RELATED TICKERS: SSN

Samson has requested that the ASX halt trading in its shares until September 24th or it can make an announcement regarding the Goshen County lease sale. I do not know what Samson is planning to announce, though Samson has done this in the past - it requested a trading halt back in April in order to raise additional capital through share issuance.  I do not know if this will also apply to the U.S. market, though it did the last time this occured. I will continue to update you as more information becomes available.

Best wishes,

Scott

Disclosure: Long SSN

Link to trading halt request: http://www.asx.com.au/asxpdf/20100922/pdf/31sn93b20n8977.pdf

葉芬

美國的SSN有Trading...

1.428 Last Done

葉芬

Buyer / Seller 亂亂來了。

Sell 1.59 / Buy 1.30



哦 現在Trading Halted了。。
剛才有誰買到了？ 1.41 至 1.45？

巨大的西瓜

1.44 already. still buy in?

葉芬

1.44 already. still buy in?
巨大的西瓜 发表于 22-9-2010 10:03 PM

Trading Halted 了，不能買進啦。
要等開盤，也許你要用2元才能買到了。

巨大的西瓜

Trading Halted 了，不能買進啦。
要等開盤，也許你要用2元才能買到了。
葉芬 发表于 22-9-2010 10:14 PM

    what yours mean? buy?

葉芬

what yours mean? buy?
巨大的西瓜 发表于 22-9-2010 10:28 PM

SSN 暫時停盤了。
要到24號 （Friday Night) 才開市。

巨大的西瓜

o.... then want buy also can't liaw lo

葉芬

o.... then want buy also can't liaw lo
巨大的西瓜 发表于 22-9-2010 10:41 PM

對。
要買可以，用更高的價錢買進了。

巨大的西瓜

走宝咯。。。。。

葉芬

走宝咯。。。。。
巨大的西瓜 发表于 22-9-2010 11:05 PM

呵呵 到時我的賣給你。2.50 就好。

仙家大炮王

芬姐，此股你怎么看？？？？？？？？
AEterna Zentaris, Inc.(NasdaqGM: AEZS)

Real Time: 1.32 0.03 (2.33%) 10:58AM EDT

AEterna Zentaris (AEZS) is a biotech company that is undervalued and deserves a much high stock price based on analyst opinions and healthy pipeline prospects. AEZS, which now is at $1.15 per share, doesn't reflect the positive opinion from the EMA (European Medicines Agency) for its lead anticancer proprietary compound, perifosine. I firmly believe AEZS is now a must own.
AEZS has out-licensed rights for perifosine to Keryx Biopharmaceuticals (KERX) for North America. I consider AEZS to be almost 100% below fair value given the enormous amount of potential world wide revenue from perifosine.
AEZS has a current marketcap of only $93M, almost zero debt, $45M cash on hand and trades at 1.5x current sales of $60M. Given the current marketcap for KERX of $261M you can clearly see how undervalued AEZS is. I am also very bullish on KERX. I have spoken with the CEO Ron Bentsur who fully believes in perifosine (you can read my detailed article earlier this year here).
In the prior trading session, AEZS had several blocks bought at $1.14, $1.15 and $1.16 totaling a 1M purchase. A trading desk rumor on AEZS being an acquisition target has created interest and possible institutional buying.
AEZS operates as a late-stage drug development company specialized in oncology and endocrinology. Its lead oncology compounds include perifosine, an orally active PI3K/Akt pathway inhibitor that is in Phase III registration trial for multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of advanced ovarian and endometrial cancer.
The company’s lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for Adult Growth Hormone Deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development..
AEZS has partnership agreements with Shionogi and Co. (SGIOF.PK), Sanofi-Aventis (SNY), ARES Trading S.A., Nippon Kayaku Co. Ltd., Spectrum Pharmaceuticals (SPPI), Handok Pharmaceuticals Co., Ltd., and Keryx Biopharmaceuticals (KERX). The company sells its products in the United States, Canada, Switzerland, the United Kingdom, the Netherlands, and Japan.

Below are some recent analyst notes:

• August 16, 2010:
  Canaccord Genuity maintains a "Speculative Buy" rating on AEZS price target $2.60. The Canaccord analyst said:

Next catalyst: Lead cancer drug perifosine has been advanced into Phase III trials in multiple myeloma and colorectal cancer and we believe that future results from these studies will be major drivers for the stock. We also look forward to important clinical and regulatory milestones for the company’s most advanced compound, AEZS-130.

• June 18th, 2010: Dundee Securities upgraded AEZS to “buy” from “neutral” but kept its price target at $2 (U.S.), based on recent stock weakness and removal of a financing overhang. Analyst David Martin writes that a financing issue this week should support operations for about 20 months based on an expected burn rate of $2.3 million per month. He said in a new report:

Optimally, AEterna would have completed a license deal for perifosine in ex-U.S. markets, and/or for its AEZS-108 drug, then issue equity at a higher stock price. Nonetheless, the financing eliminates an overhang, as it should provide a funding runway to Phase 3 results for perifosine in multiple myeloma and colorectal cancer. Both trials are expected to report results in the second half of 2011.

AEZS raised $12M selling 8.8M shares at $1.36 a share in June of this year. AEZS is currently covered by six research analysts with an average "buy" recommendation with a high target of $3 and an average $2.25 target.
If you lost money investing in Arena Pharmaceuticals (ARNA) you might want to consider buying AEZS before it doubles.